Difference between revisions of "Epithelial-cadherin precursor"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 51: | Line 51: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase interaction partners|*]] | [[Category:Tissue transglutaminase interaction partners|*]] | ||
Latest revision as of 12:16, 10 March 2015
| Epithelial-cadherin precursor | |
|---|---|
| Substrate peptide name | Epithelial-cadherin precursor |
| Synonyms | E-cadherin
Uvomorulin |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Plasma membrane |
| Swissprot ID | P12830 |
| Interacting residues | |
| Interacting sequence | |
| TG2 Swissprot ID | P21980 |
| Interacting residues of TG2 | |
| Interacting sequence of TG2 | |
| Structure | 1O6S |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:16212417 |
| Notes | |
